Immatics N.V. (NASDAQ:IMTX) Receives $15.00 Consensus Target Price from Brokerages

Shares of Immatics N.V. (NASDAQ:IMTX) have been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $15.00.

A number of brokerages have weighed in on IMTX. Guggenheim started coverage on shares of Immatics in a research report on Thursday, September 18th. They set a “buy” rating and a $16.00 price target on the stock. Zacks Research lowered shares of Immatics from a “hold” rating to a “strong sell” rating in a report on Friday, August 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a research report on Saturday, September 27th.

Immatics Price Performance

Shares of NASDAQ:IMTX opened at $9.40 on Tuesday. The business has a 50-day moving average of $6.38 and a two-hundred day moving average of $5.56. The firm has a market capitalization of $1.14 billion, a PE ratio of -14.46 and a beta of 1.22. Immatics has a 12 month low of $3.30 and a 12 month high of $11.40.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.28). The firm had revenue of $6.48 million during the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative net margin of 59.29% and a negative return on equity of 15.60%. As a group, research analysts anticipate that Immatics will post -0.72 earnings per share for the current year.

Institutional Investors Weigh In On Immatics

Large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its holdings in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after buying an additional 2,231 shares during the period. Vontobel Holding Ltd. acquired a new stake in Immatics in the second quarter valued at approximately $59,000. Intellectus Partners LLC purchased a new stake in shares of Immatics during the first quarter valued at approximately $70,000. Engineers Gate Manager LP purchased a new stake in shares of Immatics during the second quarter valued at approximately $124,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Immatics during the second quarter worth $136,000. Institutional investors and hedge funds own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.